专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210074147A1 PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF 有权
公开(公告)号：US20210074147A1
公开(公告)日：2021-03-11
申请号：US16828351
申请日：2020-03-24
申请人： AbbVie Inc.
发明人： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
IPC分类号： G08G1/01 , G08G1/04 , G08G1/015 , G01S13/86 , G01S13/91 , G06K9/00 , G06K9/62 , G08G1/042
摘要： The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

2. 发明授权

US10864196B2 Modulators of the integrated stress pathway 有权
公开(公告)号：US10864196B2
公开(公告)日：2020-12-15
申请号：US16098950
申请日：2017-05-05
申请人： Calico Life Sciences LLC , AbbVie Inc.
发明人： Marina Pliushchev , Jennifer M. Frost , Lawrence A. Black , Xiangdong Xu , Ramzi Farah Sweis , Lei Shi , Qingwei I. Zhang , Yunsong Tong , Charles W. Hutchins , Seungwon Chung , Michael J. Dart
IPC分类号： C07D413/12 , A61K31/42 , C07D271/10 , C07D471/04 , C07D271/06 , C07D401/12 , C07D233/64 , A61P3/08 , A61P25/28 , A61P9/00 , A61P35/00
CPC分类号： A61K31/42 , A61P3/08 , A61P9/00 , A61P25/28 , A61P35/00 , C07D233/64 , C07D271/06 , C07D271/10 , C07D401/12 , C07D413/12 , C07D471/04
摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

3. 发明申请

US20170157104A1 Anti-Viral Compounds 审中-公开
公开(公告)号：US20170157104A1
公开(公告)日：2017-06-08
申请号：US15431069
申请日：2017-02-13
申请人： AbbVie Inc.
发明人： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC分类号： A61K31/454 , A61K31/4184 , A61K31/4439 , A61K31/422 , A61K31/438 , A61K31/4178 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/4418 , A61K31/5377 , A61K31/4355 , A61K45/06 , A61K31/4545
CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

4. 发明授权

US09650334B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
公开(公告)号：US09650334B2
公开(公告)日：2017-05-16
申请号：US14215533
申请日：2014-03-17
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC分类号： A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC分类号： C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
摘要： The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

5. 发明申请

US20150045394A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS 有权
标题翻译：羧酰胺化合物及其作为钙蛋白酶抑制剂的用途
公开(公告)号：US20150045394A1
公开(公告)日：2015-02-12
申请号：US14522454
申请日：2014-10-23
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Andreas Kling , Helmut Mack , Katja Jantos , Achim Moeller , Wilfried Hornberger , Charles W. Hutchins
IPC分类号： C07D417/04 , C07D413/04 , C07D401/04
CPC分类号： C07D417/04 , C07D277/30 , C07D401/04 , C07D413/04
摘要： The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and/or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds.The carboxamide compounds are compounds of the general formula I in which W—R2 is selected from and R1, R2, R3a, R3b, Y1, Y2, Y3, Y4, X, Q, m, k, Rw and Rw* have the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y1, Y2, Y3 and Y4 are CRy, or one or two of the variables Y1 to Y4 are a nitrogen atom and the remaining variables are CRy, wherein the radicals Ry may be identical or different and have the meanings mentioned in the claims.
摘要翻译：本发明涉及新的羧酰胺化合物及其作为药物的用途。羧酰胺化合物是钙蛋白酶（钙依赖性半胱氨酸蛋白酶）的抑制剂。因此，本发明还涉及这些羧酰胺化合物用于治疗与钙蛋白酶活性升高相关的疾病的用途，以及通过施用有效量的这些羧酰胺化合物中的至少一种来进行治疗和/或预防性治疗的方法。羧酰胺化合物是其中W-R2选自并且R 1，R 2，R 3a，R 3b，Y 1，Y 2，Y 3，Y 4，X，Q，m，k，Rw和Rw *具有通式I的化合物权利要求中提及的其互变异构体及其药学上合适的盐。在这些化合物中，优选其中Y1，Y2，Y3和Y4为CRy，或变量Y1至Y4中的一个或两个为氮原子，剩余的变量为CRy，其中基团Ry可以相同或不同，并且具有权利要求中提及的含义。

6. 发明申请

US20140275086A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权
公开(公告)号：US20140275086A1
公开(公告)日：2014-09-18
申请号：US14215533
申请日：2014-03-17
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC分类号： C07D207/09 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D487/04 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D403/12 , C07D405/14
CPC分类号： C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
摘要： The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

7. 发明申请

US20140186377A1 PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译： PROSTAGLANDIN E2结合蛋白及其用途
公开(公告)号：US20140186377A1
公开(公告)日：2014-07-03
申请号：US14090664
申请日：2013-11-26
申请人： AbbVie, Inc.
发明人： Jijie Gu , Charles W. Hutchins , Rong-Rong Zhu , Jianwei Shen , Maria C. Harris , Eileen Belanger , Tariq Ghayur , Paul R. Hinton , Veronica M. Juan , John Mankovich , Junjian Liu
IPC分类号： C07K16/18 , A61K31/573 , A61K31/405 , A61K39/395
CPC分类号： C07K16/18 , A61K31/405 , A61K31/573 , A61K39/39533 , A61K2039/505 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , Y02A50/386 , Y02A50/401 , Y02A50/41 , Y02A50/412 , Y02A50/478 , Y02A50/481
摘要： The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
摘要翻译：本发明包括前列腺素E2（PGE2）结合蛋白。本发明涉及野生型，嵌合型，CDR移植和人源化的抗体。优选的抗体对前列腺素E2具有高亲和力，并在体外和体内中和前列腺素E2活性。本发明的抗体可以是全长抗体或其抗原结合部分。还提供了制备方法和使用本发明抗体的方法。本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性，例如在患有前列腺素E2活性有害的病症的人类受试者中。

8. 发明申请

US20220106281A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY 有权
公开(公告)号：US20220106281A1
公开(公告)日：2022-04-07
申请号：US17108416
申请日：2020-12-01
申请人： Calico Life Sciences LLC , AbbVie Inc.
发明人： Carmela Sidrauski , Marina Pliushchev , Jennifer M. Frost , Lawrence A. Black , Xiangdong Xu , Ramzi Farah Sweis , Lei Shi , Qingwei Zhang , Yunsong Tong , Charles W. Hutchins , SeungWon Chung , Michael J. Dart
IPC分类号： C07D307/82 , C07D213/74 , C07D231/14 , C07D237/10 , C07D241/12 , C07D241/44 , C07D261/08 , C07D277/32 , C07D213/57 , C07D307/56 , C07C233/74 , C07D213/54 , C07C235/54 , C07C233/79 , C07C255/41 , C07C255/57 , C07C235/14
摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式